Vol. 22/No. 09 | OncologyLive

TIL Immunotherapy Shows Promise as Second-Line Treatment of NSCLC

May 12, 2021

Investigators are studying LN-145, a novel immunotherapy developed from autologous tumor-infiltrating lymphocytes, as a potential new option for patients with unresectable or metastatic non–small cell lung cancer after disease progression on a checkpoint inhibitor and chemotherapy.

Strategies for Targeting PI3K Proliferate

May 10, 2021

Frequently dysregulated in cancer cells, the PI3K pathway has long been a high-priority therapeutic target in oncology. However, initial efforts with pan–class I PI3K inhibitors were hampered by disappointing efficacy and substantial toxicity.